Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemorad
a day ago
- #Non-small-cell lung cancer
- #Radiotherapy
- #Pneumonitis
- The study explores radiotherapy patterns and risk factors for symptomatic pneumonitis (SP) in patients with unresectable stage III NSCLC treated with durvalumab post-chemoradiotherapy.
- Most patients received concurrent chemoradiotherapy (86.6%) and intensity-modulated radiotherapy (IMRT; 66.8%), with variations observed between countries.
- Higher mean lung radiotherapy dose and prior chronic obstructive pulmonary disease (COPD) were significantly associated with increased risk of SP during durvalumab treatment.
- The odds ratios for SP were 4.73 for higher mean lung dose and 2.60 for prior COPD, indicating substantial risk increases.
- The study highlights the importance of monitoring and managing SP risks in patients undergoing consolidation durvalumab therapy for stage III NSCLC.